Dr Valérie Bourdès, Axoltis Pharma – Chief Medical Officer, will participate virtually to the Clinical Trials on Alzheimer’s Disease conference (CTAD) in Boston on November 9-12th, 2021. The results about our first-in-human clinical trial evaluating NX210 product in healthy volunteers will be presented. A good safety profile and initial promising pharmacodynamics effects are very encouraging for the future clinical development of the NX210 in patients with cognitive function impairment.